Zeballos Roberto S, da Silva Helbingen Mariely Fernanda, Melo Paulo Macio Porto, Alves Francisco Eduardo Cardoso, Salvino Caio Roberto, Seródio Ewerton Paes, de Carvalho Edimilson Ramos Migowski
D'Or Institute for Research and Education, Brazil.
Independent Researcher, Brazil.
IDCases. 2025 Jun 18;41:e02278. doi: 10.1016/j.idcr.2025.e02278. eCollection 2025.
Post-Spike Syndrome (PSS) is an emerging condition associated with the Spike protein, originating from both SARS-CoV-2 infection and mRNA-based therapies. This case series explores the significant clinical impact of PSS, characterized By gut dysbiosis, systemic inflammation, and immune activation, leading to multisystem manifestations such as fatigue, brain fog, neuropathies, and reactivation of pre-existing diseases. A simple therapeutic approach was applied to five patients, resulting in notable symptom improvement.
This case series includes five patients diagnosed with interstitial granulomatous dermatitis, polymyalgia rheumatica, peripheral polyneuropathy, drug-refractory epilepsy, and trigeminal neuralgia. A common pathophysiological mechanism-vasculitis triggered by both SARS-CoV-2 and mRNA-based therapies-was hypothesised. The patients exhibited a satisfactory response to the proposed therapeutic strategy. This is an observational and descriptive study, with data collected retrospectively from medical records at a private clinic in São Paulo, Brazil.
It is crucial to raise awareness within the medical community About SPIKEOPATHY, particularly in cases of classic pathologies that do not respond to conventional treatments. We believe PSS is currently underestimated. A broad intervention including a focus on restoring the microbiome, in particular Bifidobacterium associated with ivermectin and nattokinase was used as a therapeutic strategy. In other studies, Bifidobacterium has already been shown to significantly reduce harmful bactéria in post-COVID patients. Further studies are needed to confirm these findings and expand our understanding of PSS management.
刺突后综合征（PSS）是一种与刺突蛋白相关的新出现病症，源于严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染和基于信使核糖核酸（mRNA）的疗法。本病例系列探讨了PSS的重大临床影响，其特征为肠道菌群失调、全身炎症和免疫激活，导致疲劳、脑雾、神经病变和既往疾病复发等多系统表现。对五名患者采用了一种简单的治疗方法，症状有显著改善。
本病例系列包括五名被诊断为间质性肉芽肿性皮炎、风湿性多肌痛、周围性多发性神经病、药物难治性癫痫和三叉神经痛的患者。假设存在一种共同的病理生理机制——由SARS-CoV-2和基于mRNA的疗法引发的血管炎。患者对所提出的治疗策略表现出满意的反应。这是一项观察性和描述性研究，数据从巴西圣保罗一家私人诊所的病历中回顾性收集。
在医学界提高对刺突病的认识至关重要，尤其是在对传统治疗无反应的经典病症病例中。我们认为PSS目前被低估了。一种广泛的干预措施，包括专注于恢复微生物群，特别是与伊维菌素和纳豆激酶相关的双歧杆菌，被用作治疗策略。在其他研究中，双歧杆菌已被证明能显著减少新冠后患者体内的有害细菌。需要进一步研究来证实这些发现，并扩大我们对PSS管理的理解。
